

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Viktor MENART, et. al.  
Application No.: 10/583,157  
Filing Date: June 16, 2006  
Title: A Pharmaceutical Composition Comprising an Active Principal  
and Sulphobetaine  
Confirmation No. 5099  
Group Art Unit: 1647

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

It is respectfully requested that the documents listed on the attached Form PTO-SB/08a (EFS Web 2.1.0) be considered by the Patent and Trademark Office in the above-entitled application and made of record therein.

This statement is believed to be in compliance with the provisions of 37 C.F.R. §§ 1.97 and 1.98.

By this submission applicant is not admitting the materiality of these references. They are merely submitted to ensure full compliance with 37 C.F.R. § 1.56.

In the event a fee is required for the filing of this Information Disclosure Statement, the Commissioner is hereby authorized to charge any deficiency in the payment of the required fee(s) or credit any overpayment to **Deposit Account No. 12-2355**.

Respectfully submitted,

LUEDEKA, NEELY & GRAHAM, P.C.

By: /J. David Gonce/

J. David Gonce  
Registration No. 47,601

Date: June 18, 2009  
P.O. Box 1871  
Knoxville, TN 37901  
(865) 546-4305